Immuron Ltd.   Report issue

For profit Phase 2
Founded: Armdale Australia (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2012
NCT01466894
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

hyperimmune bovine colostrum (2 trials)

imm-124e (2 trials)

imm-529 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 2)

Communicable Diseases (Phase 2)

Fatty Liver (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Infections (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Recurrence (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3